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A 58-year-old Caucasian man was admitted for evaluation of
a nephrotic syndrome. He had a past history of mild hyperten-
sion which had been treated with a combination of hydrochlor-
othiazide and amiloride. Blood pressure was 130/70 mmHg;
there was no oedema. Serum electrolytes were normal, creati-
nine 112umol/l, albumin 29 g/l, gammaglobulin 5.3 g/1, total
cholesterol 10.2 mmol/1; 24-h urinary protein ranged from 3 to
5 g; urinary sediment was normal, and urine culture sterile. GFR
was 86 ml/min per 1.73 m2, as assesssed by I23I Iothalamate
clearance. Light microscopy and immunofluorescence studies of
the specimens obtained by percutaneous renal biopsy revealed a
typical pattern of stage 2 membranous nephropathy.
Further evaluation showed normal blood cell count, serum
complement, alphafetoprotein, and carcinoembryonic antigen;
there was absence of anti-DNA antibodies, hepatitis B virus
markers, antithyroglobulin and antimicrosomal antibodies,
cryoglobulinaemia, and mercury in urine. VDRL and FTA tests
were negative. There was no evidence of neoplasia, sarcoidosis,
or multisystemic or infectious diseases.
Drug inquiry revealed that the patient had been taking feno-
profen 600-1500 mg daily for the preceding 12 months, because
of loin pain following a vertebral trauma. Fenoprofen was with-
drawn while antihypcrtensive treatment was maintained, and
complete remission of proteinuria occurred within 6 months,
without steroid or immunosuppressive therapy, and was
persisting 2 years later.
Nephrotic syndrome induced by NSAID has been related to
minimal-change glomerulopathy and has been most often
associated with acute renal failure and severe intersitial nephritis
[1]. NSAID-associated membranous glomerulonephritis is ex-
tremely unusual. We are aware of only four reported cases, three
with diclofenac [2-4] and one with ketoprofen, a propionic-acid
derivative like fenoprofen [5]. All patients presented with the
nephrotic syndrome, and complete remission occurred in all
within 12 months of stopping the presumed causative drug.
Thus, a search for a prior NSAID treatment should be
included in the drug inquiry conducted in every patient with
membranous glomerulonephritis.
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Systemic and Disseminated Candidiasis Complicating
Renal Failure
Sir,—
We read with great interest the paper 'Systemic and dissemi-
nated candidiasis complicating acute renal failure' by Stevens
and co-workers [1].
It was rather disconcerting to note that none of their patients
were on prophylactic oral antifungal treatment. In a controlled
trial Ledingham and co-workers [2] using a Selective Parenteral
and Enteral Antisepsis Regimen (SPEAR) which included sys-
temic cefotaxime, oral polymyxin E, tobramycin and ampho-
tericin B were able to demonstrate a substantial reduction in the
incidence of acquired infection (10% vs 24%). The isolation of
yeasts from stomach, throat and trachea declined appreciably
during days 2-4 in the test group, but changed little with time in
the control group.
It has been our time-honoured practice to give nystatin
100 000 units 6-hourly to all patients admitted to our Regional
Renal Unit, irrespective of the type of renal failure, thereby
obtaining gratifying results. However, we were recently involved
in the management of a patient with acute myeloid leukaemia
who had not received oral nystatin and had developed hepatic
candidial abscesses and septicaemia; despite treatment with
amphotericin B and flucytosine, the patient died with renal
failure.
One of us (P.McC) recently investigated 27 patients who
required ventilation and dialysis for a period of more than 5
days. Cultures (1641) were taken from trachea! aspirate, urine,
wound and blood. Of 1011 cultures in 15 patients using SPEAR
therapy, 103 were positive for yeasts (10.4%). Of the 630 cul-
tures taken in the remaining 12 control patients, 137 were
positive for yeasts (21.7%). Our study is in agreement with the
findings reported by Ledingham and co-workers [2]. We cannot
but emphasise the importance of oral antifungal therapy, which
is not only a simple, but also a cheap method of preventing
candidiasis.
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More on an Easily Obtained Accurate Dialysis Index
Sir,—
The search for quantification of dialysis treatment as stimulated
by the NCDS study resulted in different approaches to collecting
data in order to calculate K xt/V (K = clearance; t = treatment
time; V = distribution volume). K was most often taken from in
vitro data provided by the manufacturers of filters, whereas the
distribution volume was either set at 0.58 x bodyweight, or was
calculated from urea extraction divided by change of blood urea
concentration before and after treatment.
We measured urea extraction by collecting dialysate, and
obtained measurements for blood urea before and after treat-
ment. Results for K. x t/V obtained from these 'true data' were
compared with those obtained from both calculated and in
vitro data. Furthermore, a formula is derived which permits
the estimation of the 'true' dialysis index from blood urea
measurements before and after treatment.
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Calculation mode
K: in vitro data
V:0.58xBW
K:in vivo data
V: 0.58 x BW
K:) in vivo dialysate
V: J and blood urea
K
225.36 ±
25.15
173.00 +
23.69*
173.00 +
23.96*
V
34.34 ±
4.56
34.34 +
4.56
39.12 +
10.95
Kxt /V
1.05 +
0.15
0.80 +
0.09*
0.74 +
0.17*
M ± S D ; n = 14;'Significance: 1 vs2, 1 vs3:/><0.001
Results (Table) indicate that the 'true' dialysis index accord-
ing to formula F3 is 25% lower than the calculated value using in
vitro clearance data and 0.58 x BW distribution volume (Fl).
Replacing the estimated clearance data by measured values
(F2) adapts the index value partially to the true finding. The
calculation of the 'true' dialysis index from extracted urea in
dialysate and concentration pre- and post-treatment included
clearance (K) = urea extracted/treatment time(cone, pre + cone. post)/2
urea extracted
urea distribution volume (V) =
cone, pre —cone, post
Combining these formulae for calculation of
Kx t1 = - results in
1 = cone, pre —cone, post(cone, pre + cone. post)/2
In conclusion, the 'true' dialysis index, taking into account
in vivo filter clearance and individually calculated distribution
volume, is easily obtained from routine pre- and post-dialysis
blood urea measurements.
Note added in proof. This formula was recently described by
Barth and Berlyne in abstract form {Kidney International 1988;
33,216)
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Treatment of Pseudomonas aeruginosa Peritonitis in a
CAPD Patient with Ciprofloxacin
Sir,—
CAPD-associated peritonitis caused by Pseudomonas aeruginosa
is a very serious complication of CAPD treatment, often
resulting in catheter removal. Ciprofloxacin, one of the new
quinolones, seems to have promising properties for the
treatment of serious Pseudomonas aeruginosa infections [1,2].
A 58-year-old woman treated by CAPD for 10 months
suffered five episodes of Staphylococcus aureus peritonitis. She
developed a further episode of peritonitis and Pseudomonas
aeruginosa was cultured from the effluent fluid. She was treated
with intraperitoneal gentamicin and ticarcillin for 8 days and
after 4 days of treatment the cultures became negative. Therapy
was continued, but after another 4 days Pseudomonas aeruginosa
was again cultured.
Ciprofloxacin was started with an initial intravenous dose of
400 mg, followed by intraperitoneal administration of 50 mg
q.d.s. Serum levels were between 0.2 and 0.6 mg/1 and peritoneal
dialysate levels varied between 1.4 and 2.2 mg/1. The mini-
mum inhibitory concentration (MIC) of ciprofloxacin for the
Pseudomonas aeruginosa strain was 0.05 mg/1. After 2 days,
dialysate cultures became negative. Because of persistent high
leucocyte counts in the peritoneal fluid, gentamicin was added to
the regimen after 8 days of ciprofloxacin therapy. The cultures
remained negative and leucocyte counts returned to normal
after another 3 days. No side-effects were observed.
Ciprofloxacin has a bactericidal action against Gram-
negative bacteria including Pseudomonas aeruginosa [3). The
quinolones have a low incidence of side-effects [4]. Ciprofloxacin
was very well tolerated by our patient. Intraperitoneal doses of
50 mg q.d.s. resulted in adequate ciprofloxacin levels in the
peritoneal dialysate, which were 30 to 40 times the MIC value of
the infecting organism. Ciprofloxacin seems to be a very promis-
ing drug in the treatment of CAPD-associated peritonitis caused
by Pseudomonas aeruginosa.
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A Modification to the 'Shaldon Technique' when Inguinal
Fibrosis is Present
Sir,—
Shaldon's introduction of the Seldinger technique to catheterise
the femoral vein [1] was a milestone in the management of the
uraemic patient. Since then thousands of patients with acute
renal failure and chronic renal insufficiency have benefited from
this procedure. However, its repeated use has occasionally
resulted in a zone of fibrous tissue in the inguinal region due to
either consecutive localised haematomas and/or the effect of the
local anaesthesia. In these cases its use is then not viable, as even
if the vessel can be localised and the guidewire inserted, the
catheter cannot be advanced because of the underlying fibrosis.
Although the development of different vascular access tech-
niques [2], the use of unipuncture systems for undertaking
haemodialysis sessions [3], or the permanence of catheters in the
femoral vein for long periods of time [4] have decreased the
incidence of this problem, it is still necessary on occasions
to resort to the use of the classic Shaldon technique for the
introduction of a vascular catheter.
We suggest a modification in the technique described by
Shaldon to introduce a femoral venous catheter through an
inguinal region when fibrosis makes its use impracticable. The
femoral vein is localised in the traditional way, using a needle of
Cournand through which a guidewire is passed. The needle is
